Abstract
ObjectiveWe carried out a bibliometric study on the scientific papers related to second-generation antipsychotic drugs (SGAs) in Malaysia.MethodsWith the SCOPUS database, we selected those documents made in Malaysia whose title included descriptors related to SGAs. We applied bibliometric indicators of production and dispersion, as Price’s law and Bradford’s law, respectively. We also calculated the participation index of the different countries. The bibliometric data were also been correlated with some social and health data from Malaysia (total per capita expenditure on health and gross domestic expenditure on R&D).ResultsWe found 105 original documents published between 2004 and 2016. Our results fulfilled Price’s law, with scientific production on SGAs showing exponential growth (r = 0.401, vs. r = 0.260 after linear adjustment). The drugs most studied are olanzapine (9 documents), clozapine (7), and risperidone (7). Division into Bradford zones yields a nucleus occupied by the Medical Journal of Malaysia, Singapore Medical Journal, Australian and New Zealand Journal of Psychiatry, and Pharmacogenomics. Totally, 63 different journals were used, but only one in the top four journals had an impact factor being greater than 3.ConclusionThe publications on SGAs in Malaysia have undergone exponential growth, without evidence a saturation point.
Highlights
Schizophrenia, with prevalence of 0.5%– 1.0% in the general population [1], has been listed as one of 10 leading disorders carrying high disability in the adult population since 2001 [2]
Division into Bradford zones yields a nucleus occupied by the Medical Journal of Malaysia, Singapore Medical Journal, Australian and New Zealand Journal of Psychiatry, and Pharmacogenomics
After studying analysed database during the period 2004–2016, we identified 105 original papers dealing with different aspects related to secondgeneration antipsychotic drugs (SGAs) in Malaysia
Summary
Schizophrenia, with prevalence of 0.5%– 1.0% in the general population [1], has been listed as one of 10 leading disorders carrying high disability in the adult population since 2001 [2]. In 1952, chlorpromazine was first discovered for treating schizophrenia [3, 4]. Chlorpromazine and its related first-generation anti-psychotic (FGA or typical anti-psychotic) drugs have efficacy of positive symptoms of schizophrenia, but produces marked distressing extrapyramidal side effects (EPS). Clozapine [5] and related second-generation anti-psychotic (SGA, or atypical anti-psychotic) were introduced, showing efficacy for both positive and negative symptoms. Since 1993, with the clinical advent of the new SGA and, later on, with their licensing in treating bipolar disorder in 2003, SGA research
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
